Skip to main content

Table 1 Baseline characteristics of study participants (n = 33)

From: Physical activity measured using wearable activity tracking devices associated with gout flares

  N (%) or mean (SD)
Age (years) 48.8 (14.9)
Sex
 Men 28 (84.9)
Race
 White* 27 (81.8)
 Black 5 (15.2)
 Other* 1 (3.0)
Education level
 Less than high school 1 (3.0)
 High school or G.E.D. 8 (24.2)
 Some college (junior college, technical degree, etc.) 13 (39.4)
 4-year college degree or higher 11 (33.3)
Age of first gout flare (years) 38.1 (18.6)
Duration of gout (years) 10.5 (8.2)
Number of flares prior 6 months
 1–3 16 (48.5)
 4–6 7 (21.2)
 > 6 10 (30.3)
Gout medication use
 Urate lowering therapy 29 (87.9)
 NSAID or colchicine 21 (63.6)
 Prednisone 12 (36.4)
Number of smartphone apps on cellphone 20.6 (17.2)
  1. NSAID non-steroidal anti-inflammatory; urate lowering therapy included allopurinol, febuxostat, or probenecid; not mutually exclusive to other gout medications
  2. *Two declared Hispanic ethnicity; missing data = 1